XML 33 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Restructuring Charges
 3 Months Ended
Mar. 31, 2018
Restructuring And Related Activities [Abstract]  
Restructuring Charges

(15) Restructuring Charges

In September 2017, the Company announced a corporate reprioritization which aimed to re-focus its resources on the core businesses of Crinone progesterone gel and JPS and reduce expenditures on research and development activities associated with the Company’s IVR program with the goal of potentially identifying a partner for one or more of its IVR product candidates. As a result, during the fiscal year ended December 31, 2017, the Company incurred approximately $0.8 million in restructuring charges. The Company accounted for these actions in accordance with ASC 420, Exit or Disposal Cost Obligations.       

 

The following table summarizes the components of the Company’s restructuring activity recorded in the accompanying balance sheets (in thousands):

 

 

 

Amounts accrued at December 31, 2017

 

 

Expense incurred

 

 

Amounts paid

 

 

Amounts accrued at March 31, 2018

 

Employee severance, benefits and related costs

 

$

72

 

 

$

—

 

 

$

(72

)

 

$

—

 

Obligations under manufacturing and development

   contracts

 

 

283

 

 

 

—

 

 

 

(113

)

 

 

170

 

 

 

$

355

 

 

$

—

 

 

$

(185

)

 

$

170

 

 

No significant additional charges are anticipated relating to this restructuring plan. The Company expects to pay approximately $0.1 million and $0.1 million during the remainder of 2018 and beyond, respectively.